HK Stock Movement | PEIJIA-B (09996) Rises Over 6% as Taurus NXT System Registration Application Accepted and Chairman Begins Share Purchase

Stock News12-08

PEIJIA-B (09996) surged more than 6%, reaching HK$5.89 by the time of writing, with a trading volume of HK$1.9895 million. The company announced on December 7 that it received an acceptance notice from China's National Medical Products Administration for the registration application of its TaurusNXT® "non-aldehyde crosslinked" dry valve transcatheter aortic valve replacement (TAVR) system.

TaurusNXT® is the company's internally developed third-generation TAVR system, utilizing patented non-aldehyde biological tissue crosslinking technology designed to enhance the durability and biocompatibility of artificial aortic valves.

Additionally, PEIJIA-B disclosed that its executive director, CEO, and board chairman, Dr. Zhang Yi, through a company under his control, began purchasing shares on the open market starting December 1, 2025. The total expected cost of the share purchases does not exceed HK$15 million. According to Dr. Zhang, the move reflects his recognition of the company's intrinsic value and his strong confidence in its growth prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment